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Abstract
Rationale The role of somatostatin and its receptors for the stress-related neuropsychiatric disorders has beenwidely raised. Recently,
we have also demonstrated the involvement of somatostatin receptor type 2-sst2R and dopamine receptor type 2-D2R in stress.
Objective In this context, we decided to find if these receptors are involved in response to antidepressant treatment in animal
model of depression—chronic mild stress (CMS).
Methods Here, we report data obtained following 7-week CMS procedure. The specific binding of [125I]Tyr3-Octreotide to
sst2R and [3H]Domperidone to D2R was measured in the rat brain, using autoradiography. Additionally, the level of dopamine
and metabolites was measured in the rat brain.
Results In the final baseline test after 7 weeks of stress, the reduced consumption of sucrose solution was observed (controls vs the
stressed animals (6.25 0.16 vs. 10.39 0.41; p < 0.05). Imipramine was administered for the next 5 weeks, and it reversed anhedonia
in majority of animals (imipramine-reactive); however, in some animals, it did not (imipramine-non-reactive). Two-way repeated
measures ANOVA revealed significant effects of stress and treatment and time interaction [F(16, 168) = 3.72; p < 0.0001], n = 10
per groups. We observed decreased binding of [125I]Tyr3-Octreotide in most of rat brain regions in imipramine non-reactive
groups of animals. The decrease of D2R after stress in striatum and nucleus accumbens and no effect of imipraminewere observed.
In the striatum and prefrontal cortex, the significant role of stress and imipramine in dopamine levels was observed.
Conclusions The results obtained in binding assays, together with dopamine level, indicate the involvement of sst2R receptors for
reaction to antidepressant treatment. Besides, the stress context itself changes the effect of antidepressant drug.
Keywords Chronic mild stress . sst2R . D2R . Dopamine level .Medial habenula nucleus . Autoradiography
Introduction
Affective disorders, including depression, are often associated
with the dysregulation of neuropeptides in various brain re-
gions. One of these neuropeptides is somatostatin (SST). SST
and its receptors (five somatostatin receptor subtypes sst1R-
sst5R) are widely distributed across the central nervous system.
SST receptors are G-protein-coupled receptors that are respon-
sible for the inhibition of adenylate cyclase, activation of po-
tassium channels, and stimulation of tyrosine kinase (Hoyer
et al. 1995). Pathophysiology in the action of SST along with
other neuromodulating systems has been implicated in depres-
sion (Pallis et al. 2001; Faron-Górecka et al. 2013). The in-
volvement of SST dysregulation in affective disorders was
suggested due to the low concentration of SST recorded in
the cerebrospinal fluid of patients with depression (Molchan
et al. 1991; Frye et al. 2003). Recently, it has been demonstrat-
ed that SST-positive GABAergic interneurons are involved in
the pathology of major depression, with a reduced expression
of SST observed in the post mortem brains of patients
(Guilloux et al. 2012; Sibille et al. 2011). It has been
demonstrated that SST is downregulated at the mRNA level
and at the precursor protein level in the anterior cingulate
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cortex and dorsolateral prefrontal cortex of depression patients
(Tripp et al. 2011; Sibille et al. 2011). Disinhibition of
somatostatin-positive GABAergic interneurons through the
use of SSTCre mice results in an anxiolytic and
antidepressant-like brain state (Fuchs et al. 2017). Because
the striatum and nucleus acumbens (NAcc) are reported to
contain both SST and its receptors, it is also possible that
SST regulates dopaminergic function in these brain areas
(Ikeda et al. 2012). Chronic antidepressant treatment influ-
ences the effects of SST on dopamine function selectively in
the NAcc (Pallis et al. 2001). SST mediates various physiolog-
ical and behavioural actions by interacting with multiple so-
matostatin receptor subtypes (Hoyer et al. 1995). In the NAcc,
the sst1 receptor (sst1R) has been reported to be an
autoreceptor for SST (Vasilaki et al. 2004; Thermos et al.
2006), whereas the sst2 receptor (sst2R) appears to be respon-
sible for the actions of SST on dopamine release and
dopamine-mediated behaviours (Thermos et al. 1996;
Hathway et al. 1999). The role of sst2R in emotional processes,
such as anxiety or depression, is well recognised (Engin and
Treit 2009). It has been demonstrated that sst2-knock out (KO)
mice have high corticosterone levels and display anxiety-like
behaviours, while both sst2KO and sst4KO mice exhibit an
antidepressant-like effect (Prévôt et al. 2017). Additionally,
the increased expression of the mRNA-encoding sst2R within
the amygdala and anterior cingulate cortex in the predator
stress model has been observed (Nanda et al. 2008). In our
previously published work, we demonstrated the involvement
of sst2R in response to 2 weeks of chronic unpredictable stress
(CMS) in rats (Faron-Górecka et al. 2016).
The full procedure of CMS allows for the identification of a
specific group of animals that do not respond behaviourally to
imipramine (IMI) treatment. Because our previous studies in-
dicated a role of sst2R in the stress response, we decided to
examine the role of sst2R in the context of the antidepressant
treatment response. Additionally, because an interaction be-
tween the somatostatin and dopamine systems has been pos-
tulated (Pallis et al. 2001), we decided to examine how CMS
affects the binding of dopamine D2 receptors and the DA
level.
Materials and methods
Animals
Male Wistar Han rats were purchased from Charles River,
Germany. The weight of the animals was nearly 300 g when
the adaptation of sucrose consumption was initiated and ap-
proximately 350 g at the start of stress procedure. Rats were
brought into the laboratory 1 month prior to the start of the
behavioural and biochemical experiments. Except when
grouping was applied as a stress parameter, they were singly
housed in plastic cages (40 × 25 × 15 cm). Food and water
were provided ad libitum, except when food or/and water
deprivation was applied as a stress parameter. The standard
12-h light/dark cycle was maintained, except during the
course of the stress regime. This study was approved by the
Bioethical Committee at the Institute of Pharmacology at the
Polish Academy of Sciences, Krakow, Poland.
Sucrose consumption test
Prior to the stress experiments, the animals were trained to
consume a sucrose solution (1%). The training procedure lasted
for 6 weeks and consisted of 1-h testing sessions every week, in
which the sucrose solution was presented to the rats in their
home cages after 14 h of food and water deprivation. Sucrose
intakewasmeasured after each drinking test as the difference in
the weight of the bottle. During the 7 weeks of stress protocol,
the sucrose consumption test was performed once a week. The
operational cut-off point between the control and stress-
reactive group was based on an arbitrary retrospective obser-
vation that was set to be a sucrose consumption of 7.5 g.
Anhedonic and IMI non-reactive (IMI-NR) animals
displayed sucrose consumption that was lower (below 7.5 g)
than the final baseline test. Animals reactive to IMI (IMI-R)
administration demonstrated an increase in sucrose intake to
above 7.5 g.
Chronic mild stress protocol
CMS experiments were performed according to the method
that has been described previously (Żurawek et al. 2015;
Faron-Górecka et al. 2014). Each week of the stress regime
consisted of two periods of food or water deprivation; two
periods of 450 cage tilt; two periods of intermittent illumina-
tion (lights on and off every 2 h); two periods of soiled cage
(250 ml water in sawdust bedding); two periods of paired
housing; two periods of low-intensity stroboscopic illumina-
tion (150 flashes/min); and two periods of no stress stimuli.
All stressors were presented for 10–14 h and were applied
individually and continuously, day and night. Animals were
deprived of food and water for 14 h preceding each sucrose
test, but otherwise food and water were freely available in the
home cage. Control animals remained undisturbed in a sepa-
rate room with free access to food and water, except for a
period of overnight deprivation prior to the sucrose consump-
tion test once a week. On the basis of their sucrose intake in
the final baseline test, animals were subjected to the CMS
procedure for 7 weeks. After the second week of the stress
procedure, the groups of animals started to receive IMI admin-
istration for the next 5 weeks (10mg/kg b.w.). Control animals
received daily injections of a vehicle (sterile saline, 1 ml/kg
b.w.). The weekly sucrose tests were performed 24 h
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following the final injection of drug or vehicle. Stress condi-
tions were continued throughout the entire period of
treatment.
Drug administration
Drug and vehicle administration was performed daily in the
morning at approximately 10.00 a.m. IMI (Sigma Aldrich,
Germany) was dissolved in physiological saline and was ad-
ministered at a dose of 10 mg/kg, i.p.
Tissue preparation
The rats were sacrificed by decapitation 24 h after the final
sucrose test. The brains were rapidly removed and frozen
using a heptane-dry ice mixture. Coronal brain sections
(12 μm) were cut using a Jung CM 3000 cryostat microtome
(Leica, Germany). The slices were thaw mounted on gelatine-
covered microscope slides, air dried, and stored at − 20 °C
until use. For measurements of the level of dopamine and its
metabolites, the appropriate brain regions were dissected out
of the removed rat brain and immediately frozen on dry ice.
Somatostatin receptor autoradiography: binding
of Tyr25[125I]-Leu8, D-Trp22
Receptor autoradiography was performed as described by
Ferone et al. 1999. Briefly, slide sections were preincubated
for 10 min in 170 mM Tris-HCl buffer, pH 7.4, and then
incubated for 60 min at room temperature (RT) in 170 mM
Tris-HCl buffer containing 5 mM MgCl2 and 1% bovine se-
rum albumin with 0.1 nM Tyr25, [125I]-Leu8, and D-Trp22
(Perkin Elmer, Germany). Non-specific binding was deter-
mined using 1 μM SST14 non-labelled rat somatostatin-14
(Prospec, Israel). After incubation, slides were dipped twice
in ice-cold Tris-HCl buffer and in ice-cold deionised H2O.
Finally, the sections were dried under a stream of cold air.
Radiolabelled sections were exposed to Kodak Biomax
XAR film (Sigma-Aldrich) for 7 days. Autoradiography im-
ages were digitised and quantified using the MCID System.
Brain regions were identified according to the rat brain atlas of
Paxinos and Watson (1986).
Dopamine D2 receptor autoradiography
Dopamine D2 receptor autoradiography was performed ac-
cording to our previous publication (Żurawek et al. 2013).
The rat brain sections were pre-incubated in 50 mM Tris-
HCl buffer (pH 7.4) at RT for 15 min to remove endogenous
dopamine. The brain slices were then incubated for 2 h at RT
in 50 mM Tris-HCl (pH 7.4) containing 120 mMNaCl, 1 mM
EDTA, 1.5 mM CaCl2, 4 mM MgCl2, and 5 mM KCl with
0.4 nM [3H]domperidone. To determine non-specific binding,
slices were treated with 10 μM (+)butaclamol and incubated
in the same binding buffer that was described previously.
After incubation, slides were dipped twice in ice-cold Tris-
HCl buffer and in ice-cold deionised H2O. The sections were
dried overnight under a stream of air. The labelled brain slices
were exposed to an imaging plate (Fujifilm, Japan) with auto-
radiography microscales (GE Healthcare) for 7 days. The
resulting autoradiograms were analysed and quantified using
ImageGauge software (Fujifilm, Japan).
Levels of DA and its metabolites: high-performance
liquid chromatography
Dopamine (DA) and its metabolites, 3,4-dihydroxyphenylacetic
acid (DOPAC) and 3-methoxytyramine (3-MT), and the final
metabolite, homovanillic acid (HVA), were assayed using high-
performance liquid chromatography with electrochemical de-
tection, under the conditions described by Wasik et al. (2007).
The tissue samples were weighed and homogenised in ice-cold
0.1 M perchloroacetic acid containing 0.05 mM ascorbic acid.
After centrifugation (10,000×g, 5 min), the supernatants were
filtered through RC 58 0.2-im cellulose membranes
(Bioanalytical Systems, West Lafayette, IN, USA). The chro-
matograph HP1050 (Hewlett-Packard, Golden, CO, USA) was
equipped with C18 columns. The mobile phase consisted of
0.05 M citrate-phosphate buffer, pH 3.5, 0.1 mM EDTA,
1 mM sodium octyl sulfonate, and 3.5% methanol. The flow
rate was maintained at 1 ml/min. The chromatographic data
were processed using the ChemStation computer program
(Hewlett Packard USA) and dopamine and its metabolites were
quantified through peak height comparisons with standards run
on the day of analysis.
Data quantification and statistical analysis
Behavioural data after 7 weeks of stress protocol and 5 weeks
of IMI treatment were analysed using two-way ANOVA re-
peated measures with stress protocol and IMI treatment as the
between subject factors and time as the within subject factor
using the Bonferroni multiple comparison post hoc test. All
groups consisted of 10 animals. Biochemical data were
analysed using two-way ANOVA with Bonferroni post hoc
test to compare all groups of experiments after 7 weeks of
stress protocol and 5 weeks of IMI treatment.
Results
Effects of chronic mild stress and imipramine
treatment on sucrose consumption
Independent analyses using repeated measures ANOVA test
did not show any significant differences in sucrose
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consumption among animals during the training procedure in
the chronic mild stress experiment [F(2, 29) = 3.485; p =
0.052]. In the final baseline test after 7 weeks of stress proto-
col, sucrose intake was significantly different between the
control animals and the animals that had been subjected to
the stress protocol (6.25 ± 0.16 vs. 10.39 ± 0.41; p < 0.05).
Administration of IMI for 5 weeks in the group of animals that
was still being subjected to the CMS protocol resulted in a
significant reduction in anhedonia, as measured by sucrose
intake. However, some animals did not respond to IMI treat-
ment in this model of depression (about 20%). Two-way re-
peated measures ANOVA revealed significant interactions be-
tween the stress protocol and IMI treatment with time [F(16,
168) = 3.72; p < 0.0001]. A significant effect of the stress pro-
tocol and IMI treatment [F(4, 168) = 9.27; p < 0.0001] and
time [F(4, 168) = 5.25; p < 0.01] was observed (Fig. 1). As a
result of the data obtained from these experiments, the follow-
ing groups of animals were selected: control; stressed; control
IMI; stress and IMI reactive (IMI-R); stress reactive and IMI
non-reactive (IMI-NR; Fig. 1).
Influence of chronic mild stress and imipramine
on the [125I]Tyr3-octreotide level in rat brain
In our studies, we used the somatostatin-28, Tyr25, [125I]-
Leu8, and D-Trp22 ([125I]Tyr3-Octreotide) as a radioligand.
This compound is a SST analogue that serves as pharmaceu-
tical octreotide acetate, which has a high affinity to sst2R and
sst5R receptors (Patel 1999). Because sst5R mRNA is present
at low levels in the adult rodents brain (Hannon et al. 2002;
Feuerbach et al. 2000) and sst5R is mainly expressed in the rat
pituitary (Shimon 2003), we can indirectly say that brain re-
ceptor autoradiography using [125I]Tyr3-Octreotide allowed
us to observe mainly sst2R binding. Such an assumption is
also supported by studies, in which the binding of this
radioligand was not detected in SST2R knockout mice
(Hannon et al. 2002). In agreement with our previous studies
(Faron-Górecka et al. 2016), a high density of SST receptors
was observed in the control and stressed or/and imipramine
treatment groups using [125I]Tyr3-Octreotide binding in dif-
ferent brain areas. Representative autoradiograms are present-
ed in Fig. 2. Data obtained in specific brain regions are pre-
sented in Table 1. In the majority of brain regions studied, the
CMS procedure increased the specific binding of [125I]Tyr3-
Octreotide. The effect of IMI administration to control, non-
stressed animals was similar in the cingulate and primary cor-
tex, as well as in the striatum and NAcc but not in the medial
habenular nucleus (MHb) nor in the hippocampus and
substantia nigra (SN). Interestingly, a subset of the group of
animals subjected to the stress protocol and IMI treatment did
not respond to the drug, as measured as a change in sucrose
consumption in most brain regions studied (except for hippo-
campus and hypothalamus); these animals showed
significantly lower specific binding of [125I]Tyr3-Octreotide
than did the stressed group.
An interaction between the stress protocol and IMI treat-
ment was observed in the basal ganglia, primary cortex, MHb,
paraventricular hypothalamic nucleus (PVP), and the CA1 of
the hippocampus. In the medial striatum, the interaction be-
tween the stress protocol and IMI treatment was considered
significant [F(2, 36) = 12.42; p < 0.0001]. Additionally, a sta-
tistically significant impact of IMI treatment was observed
[F(1, 36) = 7.38; p < 0.05]. Although, a lack of a statistical
significant effect of the stress protocol was observed [F(2,
36) = 0.97; p > 0.05 (ns)], post hoc analysis revealed a statis-
tically significant difference between the control group (not
exposed to the stress protocol) and the stressed group
[p < 0.05]. In the lateral striatum, the interaction between the
stress protocol and IMI treatment was statistically significant
[F(2, 36) = 10.81; p < 0.001], and the effects of individual
factors were different to those observed in the medial striatum.
A statistically significant impact of stress was observed
[F(2.36) = 3.334; p < 0.05], while the treatment factor was
found to be non-significant [F(1.36) = 0.13, ns]. In addition,
post hoc statistical analysis showed a significant difference
between the IMI-R and IMI-NR group, [p < 0.001]. A statis-
tically significant interaction between the stress protocol and
IMI treatment was observed in the NAcc [F(2, 54) = 13.09;
p < 0.0001]. The effect of the stress protocol and IMI treat-
ment factors in the NAcc was insignificant [(F(2, 54) = 0.66,
F(1, 54) = 4.00, respectively; ns], although the post hoc statis-
tical analysis showed significant differences between the con-
trol and stressed groups [p < 0.05]. In the PVP, a significant
interaction between the stress protocol and IMI treatment was
observed [F(2, 24) = 12.73; p < 0.0001]; the treatment factor
was also statistically significant [F(1, 24) = 5.76; p < 0.05],
while the impact of the stress factor was insignificant [F(2,
24) = 0.84; ns]. Moreover, a significant interaction between
the stress protocol and IMI treatment was observed in the
primary somatosensory cortex [F(2, 36) = 27.79; p < 0.0001]
and a significant impact of stress [F(2, 36) = 12.93;
p < 0.0001] and treatment factors [F(1, 36) = 30.46;
p < 0.0001] was observed. The post hoc analysis revealed a
statistically significant difference between the IMI-R and IMI-
NR groups [p < 0.0001]. Similar changes were revealed in the
cingulate cortex (Cg) [interaction, F(2, 54) = 14.27;
p < 0.0001; stress factor F(2, 54) = 6.74; p < 0.01; treatment
factor F(1, 54) = 25.65; p < 0.0001]. The post hoc analysis
showed significant changes between the IMI-R and stress
IMI-NR groups [p < 0.0001]. In the CA1 of the hippocampus,
the interaction between the stress and IMI treatment was sta-
tistically significant [F(2, 36) = 6.81; p < 0.01] and the stress
and treatment factors also revealed statistical differences
[stress factor, F(2, 36) = 5.17; p < 0.05; treatment factor, F(1,
36) = 41.34; p < 0.0001]. The post hoc analysis showed a sig-
nificant difference between the IMI-R and IMI-NR groups
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[p < 0.05]. In another part of hippocampus, the dentate gyrus
(DG), a significant impact of IMI treatment was observed,
while the other parameters were not significant [interaction
stress × treatment F(2, 51) = 2.26; ns; stress factor F(2,
51) = 0.29; ns; treatment factor F(1, 51) = 31.57; p < 0.0001].
The post hoc analysis showed significant differences between
Fig. 1 The scheme of full CMS procedure. The graph shows the differences in sucrose intake after full procedure of CMS. Data represents mean ±
S.E.M., n = 10 animals per group
Fig. 2 a Examined rat brain
section based on the rat brain atlas
Paxinos and Watson.
Representative autoradiograms
(b) total (c) non-specific [125I]
Tyr25,[125I]-Leu8, D-Trp22
([125I]Tyr3-Octreotide) binding
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the stressed animals (stress group) and the IMI-R [p < 0.001]
as well as between the stressed group and the IMI-NR group
[p < 0.01]. A significant effect of the stress protocol [F(2,
42) = 5.26; p < 0.01] and IMI treatment [F(1, 42) = 45.36;
p < 0.0001] was observed in the molecular layer of the dentate
gyrus (Mol), while the interaction of stress and treatment was
insignificant [F(2, 42) = 3.09; ns]. The post hoc analysis re-
vealed a significance difference between the stressed animals
(stress group) and the IMI-R group [p < 0.0001]. A significant
interaction between the stress and IMI treatment was observed
in the MHb [F(2, 48) = 7.36; p < 0.01]. In this structure, a
statistically significant impact of IMI treatment was observed
[F(1, 48) = 14.72; p < 0.001], while the effect of the stress
factor was not significant [F(2, 48) = 2.64; ns]. However, post
hoc analysis revealed a statistically significant difference be-
tween the control and stressed groups [p < 0.05]. Similar data
were obtained for the SN, where the interaction between the
stress protocol and IMI treatment was significant [F(2, 51) =
3.43; p < 0.05], while the effect of the stress factor was not
significant [F(2, 51) = 1.31; ns] and the effect of IMI treatment
was considered to be significant [F(1, 51) = 22.94;
p < 0.0001]. The lack of a significant interaction between the
stress and IMI treatment was observed in the anterodorsal part
of the medial amygdaloid nucleus (MeAD) [interaction, F(2,
36) = 1.40; ns], while the treatment factor was highly signifi-
cant [treatment factor, F(1, 36) = 24.20; p < 0.0001] and the
impact of stress was also statistically significant [stress factor,
F(2, 36) = 3.75; p < 0.05]. For the anterior part of the
basolateral amygdaloid nucleus (BLA), only a significant im-
pact of IMI treatment was observed [F(1, 30) = 10.46;
p < 0.01]. For the other parameters, two-way ANOVA analy-
ses did not show differences of statistical significance [inter-
action stress × treatment (F(2, 30) = 0.94; ns; stress factor F(2,
30) = 2.29; ns]. Both for the central part of the anterior hypo-
thalamic area (AHC) and the posterior part of the
paraventricular thalamic nucleus (PA), a significant effect of
IMI treatment was observed [F(1, 18) = 5.80; p < 0.05; F(1,
36) = 4.64; p < 0.05, respectively]. There were no statistically
significant effects of the remaining parameters [AHC: interac-
tion F(2, 18) = 0.3648; ns; stress factor F(2, 18) = 0.21; ns;
and PA: interaction F(2, 36) = 1.34; ns; stress factor F(2,
36) = 0.48; ns]. Data obtained in the dorsal endopiriform nu-
cleus (Den) and the interfascicular nucleus (IF) did not show
any statistical differences [Den: interaction F(2, 48) = 0.99;
ns; stress factor F(2, 48) = 0.70; ns; treatment factor F(1,
48) = 0.49; ns; IF: interaction F(2, 30) = 1.45; ns, stress factor
F(2, 30) = 0.91; ns, treatment factor F(1, 30) = 2, 08; ns].
Effect of chronic mild stress on dopamine D2R
expression
For the dopamine D2 receptor binding, we used
[3H]Domperidone. The results are presented in Fig. 4.
Specific binding was observed in the striatum (lateral and
medial parts) and in the NAcc and nucleus accumbens shell
(NAcs; Fig. 3). After 7 weeks of stress, a decrease in specific
Table 1 Specific binding of [125I] Tyr25,[125I]-Leu8, and D-Trp22 in rat brain after CMS procedure. Data represent as optical density (O.D.) ± S.E.M.
Structures [125I] Tyr25,[125I]-Leu8, D-Trp22 binding [O.D. ± S.E.M.]
Control Stress Control IMI IMI R IMI NR
Primary cortex 47,206 ± 552 49,943 ± 237a 49,603 ± 463 46,407 ± 881 38,349 ± 1917d,e
Cingulate cortex 47,277 ± 632 50,194 ± 20 a 47,617 ± 477 47,621 ± 472 40,712 ± 2136d,e,f
Dorsal endopiriform nucleus 47,484 ± 538 47,752 ± 582 47,686 ± 592 47,821 ± 536 46,514 ± 633
Striatum, medial part 22,784 ± 1167 29,902 ± 2216 a 28,396 ± 1610 23,815 ± 928 19,078 ± 928
Striatum, lateral part 10,235 ± 839 130,402 ± 1205 13,500 ± 916 11,982 ± 519 7002 ± 896
Accumbens nucleus, core 18,742 ± 1467 25,061 ± 1177 a 24,765 ± 2357 20,151 ± 1295 16,783 ± 1132d,e
field Ca1 of hippocampus 47,261 ± 689 50,222 ± 14 45,930 ± 208b 47,142 ± 514 43,956 ± 1283d,f
dentate gyrus 37,103 ± 2111 40,813 ± 1263 33,590 ± 2079b 30,780 ± 1314c 32,322 ± 1496d
Anterior hypothalamic area, central part 23,190 ± 2904 26,375 ± 5126 21,713 ± 1026 18,817 ± 1594 14,714 ± 1855
Medial habenular nucleus 44,019 ± 605 49,628 ± 426 a 45,353 ± 849 43,143 ± 2275c 44,595 ± 644d
Molecular layer of the dentate gyrus 47,381 ± 253 50,164 ± 53a 45,212 ± 1383b 46,766 ± 461c 44,703 ± 888d
Paraventricular hypothalamic nucleus 25,730 ± 2191 28,394 ± 1401 25,407 ± 1035 25,527 ± 2116 22,365 ± 1332
Paraventricular thalamic nucleus, posterior part 18,921 ± 3224 27,268 ± 2066 26,923 ± 1728 19,544 ± 1687 14,258 ± 2747d, e
Basolateral amygdaloid nucleus, anterior part 47,627 ± 496 49,482 ± 620 46,888 ± 624b 47,642 ± 415 47,018 ± 645
Medial amygdaloid nucleus, anterodorsal part 46,939 ± 505 49,135 ± 501 40,551 ± 2319b 46,082 ± 776 41,482 ± 2275d
Interfascicular nucleus 28,075 ± 4990 38,640 ± 3937 31,228 ± 3904 29,517 ± 2862 30,412 ± 1896
Substantia nigra 16,754 ± 954 19,430 ± 907 15,749 ± 837 15,804 ± 984 13,913 ± 706d
a p < 0.05 vs control group; b p < 0.05 vs stress group; c p < 0.05 vs control IMI group; c,d p < 0.05 vs stress group; e p < 0.05 vs IMI-R group
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binding in all labelled structures was observed. A statistically
significant impact of stress was observed in the lateral part of
striatum [F(1, 24) = 11.91; p < 0.01], while the effect of IMI
treatment was not significant [F(2, 24) = 0.33; ns]. Similarly,
in the medial part of the striatum, a statistically significant
effect of the stress was observed [F(1, 21) = 8.14; p < 0.01].
Post hoc analysis revealed a statistically significant difference
between control and stressed groups [p < 0.05]. However, the
two-way ANOVA did not show any statistically significant
changes. In the NAcc and NAcs, the stress protocol induced
a significant decrease in the binding of [3H]Domperidone
[p < 0.05] (Fig. 4).
Effect of CMS on DA and its metabolites in the PFC,
striatum, and hypothalamus
Our results indicate a significant role of stress in the levels of
DA in the PFc and striatum, with a statistically significant
effect of stress on the level of 3-MT in the striatum and an
interaction between stress and IMI treatment (Table 2). In the
PFc, the impact of stress on the level of DAwas considered to
be significant [F(1, 18) = 20.87; p < 0.001], despite the lack of
a statistically significant effect of IMI treatment [F(2, 18) =
0.86; ns]. Similar changes were observed in the level of
DOPAC [impact of stress F(1, 18) = 5.71; p < 0.05; impact
of treatment F(2, 18) = 1.23; ns]. As far as the levels of 3-
MT and HVA are concerned, a statistically significant impact
of IMI treatment was observed [F(2, 18) = 6.58; p < 0.01 and
F(2, 18) = 3.60; p < 0.05, for 3-MT and HVA respectively]. A
statistically significant impact of stress was observed in the
DA level in the striatum [F(1, 18) = 6.573; p < 0.05]. Two-
way ANOVA analysis revealed an interaction between stress
and IMI treatment [F(2, 18) = 5.622; p < 0.05] and a statisti-
cally significant effect of stress on the level of 3-MT [F(1,
18) = 11.79; p < 0.01]. For other metabolites (DOPAC and
HVA), analysis did not show any significant effects. In the
hypothalamus, we did not observe any significant changes in
the levels of DA, 3-MT, or HVA. The impact of stress in the
hypothalamus produced a significant change in the level of
DOPAC only [F(1, 18) = 5.84, p < 0.05].
Discussion
CMS and response to antidepressant treatment
Following the CMS procedure, a reduced sucrose intake was
recorded in a selection of animals in response to stress stim-
ulus and treatment with imipramine (IMI) returned these
animals to a normal level of sucrose consumption (IMI-R).
Additionally, this model allowed for the identification of the
animals who did not respond behaviourally to antidepressant
treatment (IMI-NR). The percentage of animals that is IMI-
NR is usually approximately 30% of the tested animals
(Faron-Górecka et al. 2014; Żurawek et al. 2015; Faron-
Górecka et al. 2017). This result highlights an advantage of
this animal model of depression (for review: Willner 2016),
which is the expression of a treatment-resistant model of
depression, as is frequently encountered in patients in the
clinic.
CMS model reflects the dynamic process of brain
response to stress stimuli
One of the goals of the present study was to find a marker of
drug resistance. The involvement of neuropeptides in mental
disorders and in the mechanism of action of drugs has been
postulated. In our previously published studies, we have dem-
onstrated a significant negative correlation between basal pro-
lactin levels (i.e., before the CMS procedure) and the behav-
ioural response to IMI administration (Faron-Górecka et al.
2017). Recently, we also highlighted the role of sst2R in the
stress reaction (Faron-Górecka et al. 2016; Faron-
Górecka & Szafran-Pilch 2016). In the present study, we in-
vestigated the role of sst2R in response to IMI treatment fol-
lowing an extended period (7 weeks) of the CMS protocol.
Following this experimental paradigm, increased [125I]Tyr3-
Octreotide binding was observed in all brain regions involved
in the stress reaction. These results are contrary to the effect of
a shorter period of the CMS protocol (2 weeks), which resulted
in a decrease in sst2R binding in the studied brain regions (with
the exception of the MHb, where an increase in sst2R binding
was observed, Faron-Górecka et al. 2016). However, the op-
posing effects of 2 and 7 weeks of the CMS protocol are not
surprising. In our previously published papers, we observed
dynamic changes that were dependent on the duration of stress
at the levels of prolactin (Faron-Górecka et al. 2014).
Additionally, the alterations in the dopamine D2 receptor bind-
ing were dependent on the duration of the CMS protocol
(Żurawek et al. 2013). The observed fluctuations were ob-
served not only at the level of receptors or neuropeptides but
also at themicroRNA (miRNA) level. Using the CMS protocol
and studying the differences between stress-reactive and stress-
resilient groups of animals, we observed fluctuations in
miRNA 16 depending on the duration of the stress stimuli
(Żurawek et al. 2016). It appears that the CMS model reflects
the dynamic process of the brain response to stressful stimuli,
which can further contribute to the development of depression.
Role of medial habenula nucleus in the stress
response
An interesting result in this study is the increase in the binding
to sst2R in the MHb. The habenula is a small, evolutionarily
conserved brain structure that plays a central role in aversive
processing and is hypothesised to be hyperactive in
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depression, contributing to the generation of symptoms such
as anhedonia (Lawson et al. 2017; Liu et al. 2017). Recently, it
has been shown that dorsalMHb-lesionedmice exhibit shorter
immobility time in the tail suspension test, another model of
depression. Dorsal MHb-lesioned mice also display increased
vulnerability to the induction of learned helplessness (Hsu
et al. 2016). Statistically significant changes in the sst2R bind-
ing in this structure are the result of stress, whereas IMI, irre-
spective of the response to the treatment, produced a normal-
isation of this effect. Thus, it appears that the MHb is a stress-
sensitive region that may be an interesting site for the study of
stress resilience rather than treatment resistance (due to the
lack of differences between the IMI-R and IMI-NR groups).
Analogous changes in sst2R binding in the stress-reactive
group were observed in the BLA and MeAD. Increased
sst2R binding can be correlated with data observed by
Nanda et al. (2008), who reported that rats respond to acute
ferret exposure with a significant increase in fearful and anx-
ious behaviours that are accompanied by robust amygdala
activation and an increase in the expression of mRNA
encoding sst2R within the amygdala and anterior cingulate
cortex. Authors concluded that this data may represent one
mechanism by which psychological stress is associated with
adaptive and maladaptive behavioural responses (Nanda et al.
2008). In our studies, we also observed an increase in sst2R
binding in the cingulate and primary cortex, which may also
Fig. 4 Specific binding of [3H]Domperidone. Data was normalised to % of control and represented as mean ± S.E.M.
Fig. 3 a Examined rat brain section based on the rat brain atlas Paxinos and Watson. Representative autoradiograms (b) total (c) non-specific
[3H]Domperidone binding
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be relevant to the data described above. Interestingly, within this
structure, we observed a statistically significant decrease in sst2R
binding in the group of animals that were non-responsive to IMI
treatment compared to the sst2R binding in the rats that
behaviourally responded to the drug. Because it has been shown
that antidepressants increase the level of SST in the PFc (Pallis
et al. 2009), the reduction of SST receptors in the rats that were
subjected to CMS and did not respond to IMI may indicate the
involvement of SST receptors in the mechanisms of drug resis-
tance in these animals. Moreover, it appears that the brains of
animals that did not react behaviourally to IMI treatment are
more sensitive to the drug treatment. After long-term CMS, in-
creased sst2R binding was observed, while IMI treatment re-
versed this effect to the level of control in the IMI-R group. In
drug-resistant animals, the reaction to IMI treatment is somehow
excessive, and a statistically significant decrease in sst2R binding
was observed. A similar effect was observed in structures in the
basal ganglia. This effect is relevant to the observation that re-
fractory depression is associated with disrupted functional con-
nectivity mainly in thalamo-cortical circuits (Lui et al. 2011).
Potential interaction of two receptors: sst2R and D2R
Recently, an association between thalamic hyperactivity with
treatment-resistant depression and a poor response in early
treatment for major depression has been shown (Yamamura
et al. 2016). Long-term CMS (7 weeks) as well administration
of IMI (5 weeks) caused an increase in the binding of
[125I]Tyr3-Octreotide in the striatum, especially in the medial
part, as well as in the NAcc. SST is synthesised in the nuclei of
the basal ganglia (e.g., the striatum and NAcc), and the dysreg-
ulation of SST is implicated in motor and affective disorders
(Brownstein et al. 1975; Vincent and Johansson 1983).
However, cortical and subcortical SST has been implicated in
the pathophysiology of psychiatric disorders (Rubinow 1986).
Because the striatum and NAcc are reported to contain both
SST and its receptors, it is possible that SST regulates dopami-
nergic function in these brain areas (Ikeda et al. 2012). It has
been shown that SST infusion in the striatum leads to increased
DA levels, however without changes in the DA metabolites:
HVA and DOPAC (Thermos et al. 1996; Hathway et al. 1998;
Marazioti et al. 2008). The sst2R appears to be responsible for
the actions of SST on DA release and dopamine-mediated be-
haviours (Raynor et al. 1993; Thermos et al. 1996; Hathway
et al. 1999). Thus, the observation of increased sst2R binding
after long-lasting stress in the striatum or NAcc can result in the
regulation of the dopamine D2R. Using [
3H]Domperidone
binding analysis, we observed a significant decrease in the ex-
pression of D2R in the tested brain regions and this effect was
only significant in the group of animals that behaviourally
reacted to stress by reducing their sucrose intake. This finding
remains in agreement with our previous work, which demon-
strated a regulation of D2R expression in response to stress:
CMS decreased dopamineD2RmRNA expression and receptor
density in the mesoaccumbens circuit in stress-reactive animals
(Puglisi-Allegra et al. 1991; Papp et al. 1994; Dziedzicka-
Wasylewska et al. 1997; Cabib et al. 1998; Zhu et al. 2010;
Żurawek et al. 2013). Conversely, D2R density increased after
chronic antidepressant treatment, which supports the potential
involvement of D2R in antidepressant efficacy (Gershon et al.
2007; Dunlop and Nemeroff, 2007). In the present study, using
[3H]Domperidone, we observed an increase in D2R binding
upon chronic IMI treatment but this effect did not reach statis-
tical significance. It has been shown that chronic desipramine
(DMI) treatment results in an exaggerated somatostatin-
induced increase in dopamine levels, specifically in the NAcc.
Whereas, acute DMI treatment had no effect compared with
saline-treated rats. Basal concentrations of DA and its metabo-
lites were not shown to be influenced by either chronic or acute
treatment of DMI in either brain area. These results demonstrate
that SST can regulate DA release in the NAcc and striatum
(Pallis et al. 2006). Likewise, it has been reported that DA
administration regulates SST release (Rodriguez-Sanchez
et al. 1997) and that selective DA receptor agonists increase
Table 2 Dopamine and metabolites levels in rat brain after CMS
procedure
(a) DA and metabolites levels in PFc
PFc—7 weeks of stress and 5 weeks of imipramine treatment
Treatment N [DA] [DOPAC] [3-MT] [HVA]
Control 4 1450 ± 199 310 ± 35 60 ± 9.1 155 ± 19
Stress reactive 4 1669 ± 130 383 ± 35 65 ± 9.3 190 ± 35
Control IMI 4 1269 ± 137 315 ± 25 42 ± 2.9 117 ± 13
Stress IMI R 4 1726 ± 86 317 ± 14 37 ± 6.2 119 ± 7
Stress IMI NR 4 2068 ± 53a 399 ± 23a 53 ± 4.9 184 ± 23a
(b) DA and metabolites levels in striatum
Striatum—7 weeks of stress and 5 weeks of imipramine treatment
Treatment N [DA] [DOPAC] [3-MT] [HVA]
Control 4 11,778 ± 467 1343 ± 64 482 ± 26 726 ± 84
Stress reactive 4 12,973 ± 909 1338 ± 82 508 ± 28 807 ± 84
Control IMI 4 11,594 ± 528 1420 ± 97 535 ± 43 678 ± 25
Stress IMI R 4 12,605 ± 222 1331 ± 96 344 ± 13b 595 ± 43
Stress IMI NR 4 13,522 ± 974 1530 ± 73 425 ± 33 837 ± 87a
(c) DA and metabolites levels in hypothalamus
Hypothalamus—7 weeks of stress and 5 weeks of imipramine treatment
Treatment N [DA] [DOPAC] [3-MT] [HVA]
Control 4 349 ± 28 36 ± 4.0 10 ± 2.9 26 ± 4.1
Stress reactive 4 384 ± 30 52 ± 4.1b 13 ± 0.6 27 ± 4.9
Control IMI 4 358 ± 26 47 ± 1.4 21 ± 2.9 29 ± 5.3
Stress IMI R 4 373 ± 25 47 ± 5.5 13 ± 4.5 22 ± 2.2
Stress IMI NR 4 425 ± 46 58 ± 7.6 15 ± 2.6 33 ± 4.9a
Data represent mean ± S.E.M
a p < 0.05 indicates the statistical significant between stress IMI NR vs
stress IMI R groups
b p < 0.05 indicates the statistical significant between stress vs control
groups
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SST receptor density in the striatum (Izquierdo-Claros et al.
1997). In our study, we measured the levels of DA and its
metabolites in the PFc, striatum, and hypothalamus of rats that
had been subjected to CMS. Mesolimbic and mesocortical DA
is thought to play a role in the processing of rewards; however,
other studies also demonstrate that DA release occurs in re-
sponse to aversive stressful stimuli (Pruessner et al. 2004).
The observed decrease in D2R binding in the stress-reactive
group had no direct impact on the DA level in the striatum.
Notably, in this group of animals, we observed increased
sst2R binding. This may indicate that the D2R does not undergo
conventional internalisation, but rather indicates the potential
interaction of these two receptors, the sst2R and the D2R. The
interaction between the dopaminergic and somatostatinergic
systems is considered to play a potential role in mood regula-
tion. Our previous studies have shown that D2R and sst5R het-
erodimers can be considered as potential mediators of the effect
of antidepressants, as the heterodimerization of these receptors
occurs in native brain tissue as well as in primary striatal neu-
ronal cultures where receptors are expressed at physiological
levels. Moreover, antidepressant drugs promote the formation
of these heterocomplexes in the mouse striatum (Szafran-Pilch
et al. 2017). Chronic administration of antidepressants influ-
ences the release of both these neurotransmitters (Pallis et al.
2009; Pallis et al. 2006; Pallis et al. 2001). The changes ob-
served in the binding of sst2R and the level of DA in the groups
of animals that were subjected to long-term CMS indicate that
the stress context itself changes the effect of the antidepressant
drug. Our results indicate a significant role of stress in the level
of DA in the PFc and the striatum, with a statistically significant
effect of stress on 3-MT release in the striatum and an interac-
tion of stress and IMI treatment. However, these results depend
of the behavioural reaction to IMI treatment. Exposure to a
single stress stimulus, such as a restrain session, promotes an
increase in the expression of DA in the PFc (Abercrombie et al.
1989). Using an alternative stress protocol, it has been demon-
strated that animals exposed to CVS (chronic variable stress)
exhibit a larger increase in cortical DA release in response to the
restrain events than rats that were not exposed to a prior CVS
regime (Cuadra et al. 1999). Similarly, in the striatum, it has
been demonstrated that reduced reactivity toward noxious stim-
uli in animals following chronic stress corresponds with a re-
duced level of extracellular DA in the NAcc (Gambarana et al.
1999). Moreover, it has been demonstrated that, in some mice
strains, exposure to an acute stressor induces an increase in
DOPAC accumulation as well as a pronounced reduction of
DA in the NAcc, while in other mice strains, these variations
are less pronounced or entirely absent (Shanks et al. 1991)
suggesting a close relationship between genetic or epigenetic
variations and the sensitivity of the mesolimbic system and
behavioural alterations which are produced by acute or chronic
stress (Ventura et al. 2001; Pani et al. 2000). However, it has
been demonstrated that sst2R functionally influence the
physiology of the globus pallidus (GP) and modulate the loco-
motor activity of the rat. Activation of this receptor modulates
the GP-striatum circuity and increases DA levels in the striatum
(Marazioti et al. 2008). This data can be related to our data,
suggesting an association between DA levels and sst2R bind-
ing. Our data revealed that IMI treatment influenced the level of
DA and its metabolites (3-MT and HVA) in the PFc. However,
Cuadra et al. (2001) did not show changes in DA in the frontal
cortex after antidepressant drugs treatment. These authors dem-
onstrated that repeated administration of antidepressants
blocked the sensitised DA output in response to restrain follow-
ing CSVexposure (Cuadra et al. 2001). An interesting finding
of our study is the decreased level of DA in the PFc that was
observed in the IMI-R group of animals, while the IMI-NR
group showed DA levels comparable to those of the stressed
group (Table 2). This suggests that animals that do not respond
to IMI have impaired regulation of DA biosynthesis, providing
further evidence that this group is overactive.
Sst2R level is regulated by CMS in PVP
The increased level of sst2R binding observed in the PVP
following stress or IMI treatment is another interesting finding
of this study. It has been shown that the PVP plays a role in the
regulation of stress and negative emotional behaviour (Hsu
et al. 2014). Located in the dorsal midline thalamus, the
PVP is heavily innervated by neurotransmitters and is the only
thalamic nucleus that is connected to the group of structures
comprising the amygdala, NAcc, and infralimbic/subgenual
anterior cingulate cortex (sgACC). These neurotransmitter
systems and structures are involved in regulating motivation
and mood and display abnormal functioning in several psy-
chiatric disorders including anxiety, substance use, and major
depressive disorders. Furthermore, rodent studies show that
the PVP is consistently and potently activated following a
variety of stressors and has a unique role in regulating re-
sponses to chronic stressors. These findings provide compel-
ling reasons to study the PVP in relation to stress and negative
emotional behaviour and for including the PVP in the neural
pathways involved in stress-related psychiatric disorders (Hsu
et al. 2014).
Lack of involvement of hippocampal sst2R
in treatment resistance depression
In all of the parts of hippocampus that were studied, we ob-
served the significant impact of treatment and stress on sst2R
binding. It has been demonstrated that both hippocampal sst2
and sst4 receptors selectively inhibit stress-induced HPA axis
activation but mediate anxiolytic and antidepressive effects
through distinct mechanisms (Prévôt et al. 2017). In our study,
we observed a decrease in the binding of sst2R in all groups,
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regardless of the behavioural effect following IMI treatment.
This may indicate a lack of involvement of sst2R in hippocam-
pal structures in the treatment resistance depression that was
induced by using CMS.
Conclusion
The obtained results indicate an involvement of sst2R in CMS,
which is a widely used animal model of depression. In addition,
we demonstrate a role of this receptor in response to treatment
with IMI; the group of animals that is not responsive to IMI is
more sensitive in this context, which is manifested by excessive
regulation of the expression of the sst2R receptor and level of
DA. The results obtained in sst2R and D2R binding assays,
together with the measurement of the levels of DA and its me-
tabolites in the brain, indicate an involvement of these two re-
ceptors in key brain structures involved in the response to chron-
ic stress and antidepressant therapy sensitivity. In addition, we
demonstrate that the primary cortex, cingulate cortex, striatum,
and NAc are brain regions that are significant in this context.
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